FDA Peptide Review Sparks Legal Battle | Washington DC News

The FDA is under fire as it reviews a list of compounded peptides—popular in wellness and longevity circles—that could soon vanish from clinics unless approved. EVEXIAS Life Sciences is suing, claiming the agency unjustly restricted 17 peptides without solid justification. While regulators worry about unapproved drugs, proponents argue regulated compounding pharmacies ensure safety. With demand soaring for alternative treatments, experts urge caution against DIY peptide mixes online—risking contamination and wrong dosages. The FDA’s decision could reshape access to these trending therapies, so always get them from licensed practitioners through registered pharmacies. Thank you to our sponsor Garrett Waller Performance: http://coaching.garrettwaller.com Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/d3cbc6402dfcee5d